Daniela Baldoni

787 total citations
19 papers, 613 citations indexed

About

Daniela Baldoni is a scholar working on Infectious Diseases, Molecular Biology and Oncology. According to data from OpenAlex, Daniela Baldoni has authored 19 papers receiving a total of 613 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Infectious Diseases, 5 papers in Molecular Biology and 4 papers in Oncology. Recurrent topics in Daniela Baldoni's work include Antimicrobial Resistance in Staphylococcus (5 papers), Advanced Breast Cancer Therapies (3 papers) and Orthopedic Infections and Treatments (3 papers). Daniela Baldoni is often cited by papers focused on Antimicrobial Resistance in Staphylococcus (5 papers), Advanced Breast Cancer Therapies (3 papers) and Orthopedic Infections and Treatments (3 papers). Daniela Baldoni collaborates with scholars based in Switzerland, United States and Italy. Daniela Baldoni's co-authors include Andrej Trampuž, Werner Zimmerli, Manuel Haschke, Andrea Steinhuber, Jasper Dingemanse, Katharina Rentsch, Patrick Schaerli, Z. Rajacic, Reno Frei and Marcelo M. Gutierrez and has published in prestigious journals such as Blood, Cancer Research and International Journal of Molecular Sciences.

In The Last Decade

Daniela Baldoni

19 papers receiving 601 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Daniela Baldoni Switzerland	12	246	222	163	101	62	19	613
C. Eftimiadi Italy	15	40 0.2×	55 0.2×	162 1.0×	107 1.1×	45 0.7×	33	645
Recep Keşli Türkiye	12	81 0.3×	136 0.6×	79 0.5×	172 1.7×	7 0.1×	46	560
Lorenzo Zaffiri United States	12	122 0.5×	88 0.4×	95 0.6×	159 1.6×	3 0.0×	37	654
Adam Johnson United States	20	325 1.3×	31 0.1×	189 1.2×	367 3.6×	4 0.1×	57	1.1k
S. de Marie Netherlands	16	336 1.4×	211 1.0×	57 0.3×	279 2.8×	3 0.0×	22	726
Charlene Desbonnet United States	11	104 0.4×	35 0.2×	119 0.7×	134 1.3×	2 0.0×	15	543
Michaela Metz Germany	7	161 0.7×	123 0.6×	115 0.7×	79 0.8×	2 0.0×	11	428
Koji Takemoto Japan	16	193 0.8×	128 0.6×	73 0.4×	191 1.9×	2 0.0×	55	656
C. Heymans Belgium	9	152 0.6×	21 0.1×	63 0.4×	116 1.1×	14 0.2×	12	349
Gunnar Hopen Norway	14	80 0.3×	112 0.5×	155 1.0×	79 0.8×	2 0.0×	25	541

Countries citing papers authored by Daniela Baldoni

Since Specialization

Citations

This map shows the geographic impact of Daniela Baldoni's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniela Baldoni with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniela Baldoni more than expected).

Fields of papers citing papers by Daniela Baldoni

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniela Baldoni. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniela Baldoni. The network helps show where Daniela Baldoni may publish in the future.

Co-authorship network of co-authors of Daniela Baldoni

This figure shows the co-authorship network connecting the top 25 collaborators of Daniela Baldoni. A scholar is included among the top collaborators of Daniela Baldoni based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniela Baldoni. Daniela Baldoni is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

Rogers, Kerry A., Pearlly S. Yan, Ian W. Flinn, et al.. (2023). Abstract CT021: Assessing clinical and pharmacodynamic (PD) profiles of patients (pts) with chronic lymphocytic leukemia (CLL) on ianalumab (VAY736) + ibrutinib. Cancer Research. 83(8_Supplement). CT021–CT021. 1 indexed citations

Pearson, David, Yi Jin, Andrea A. Romeo, et al.. (2022). Species-dependent hepatic and intestinal metabolism of selective oestrogen receptor degrader LSZ102 by sulphation and glucuronidation. Xenobiotica. 52(1). 26–37. 2 indexed citations

Groarke, Emma M., Bhavisha A. Patel, Fernanda Gutierrez‐Rodrigues, et al.. (2021). Eltrombopag added to immunosuppression for children with treatment‐naïve severe aplastic anaemia. British Journal of Haematology. 192(3). 605–614. 36 indexed citations

Baldoni, Daniela, Michela Varani, Filippo Galli, et al.. (2019). Comparison of 99mTc-UBI 29-41, 99mTc-ciprofloxacin, 99mTc-ciprofloxacin dithiocarbamate and 111In-biotin for targeting experimental Staphylococcus aureus and Escherichia coli foreign-body infections: an ex-vivo study. The Quarterly Journal of Nuclear Medicine and Molecular Imaging. 63(1). 37–47. 9 indexed citations

Groarke, Emma M., Bhavisha A. Patel, Fernanda Gutierrez‐Rodrigues, et al.. (2019). Outcomes in Pediatric Patients with Severe Aplastic Anemia Treated with Standard Immunosuppression and Eltrombopag. Blood. 134(Supplement_1). 454–454. 11 indexed citations

Curigliano, Giuseppe, Sara Cresta, Dejan Juric, et al.. (2019). Abstract OT1-03-01: Phase 1/1b study of novel oral selective estrogen receptor degrader (SERD) LSZ102 in combination with alpelisib (BYL719) in estrogen receptor-positive (ER+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC) with progression on endocrine therapy (ET). Cancer Research. 79(4_Supplement). OT1–3. 1 indexed citations

Jhaveri, Kartik, Giuseppe Curigliano, Sara Cresta, et al.. (2019). Abstract PD1-08: Phase 1/1b study of novel oral selective estrogen receptor degrader (SERD) LSZ102 for estrogen receptor-positive (ER+) advanced breast cancer (ABC) with progression on endocrine therapy (ET). Cancer Research. 79(4_Supplement). PD1–8. 3 indexed citations

Juif, Pierre‐Éric, Daniela Baldoni, Darren Wilbraham, et al.. (2017). Pharmacokinetics, Pharmacodynamics, Tolerability, and Food Effect of Cenerimod, a Selective S1P1 Receptor Modulator in Healthy Subjects. International Journal of Molecular Sciences. 18(12). 2636–2636. 12 indexed citations

Welford, Richard W.D., Andreas Mühlemann, David A. Priestman, et al.. (2017). Lucerastat, an iminosugar for substrate reduction therapy in Fabry disease: preclinical evidence. Molecular Genetics and Metabolism. 120(1-2). S139–S140. 7 indexed citations

10.

Baldoni, Daniela, Robert Waibel, Peter Bläuenstein, et al.. (2015). Evaluation of a Novel Tc-99m Labelled Vitamin B12 Derivative for Targeting Escherichia coli and Staphylococcus aureus In Vitro and in an Experimental Foreign-Body Infection Model. Molecular Imaging and Biology. 17(6). 829–837. 14 indexed citations

11.

Baldoni, Daniela, et al.. (2015). Bioequivalence of different dose-strength tablets of selexipag, a selective prostacyclin receptor agonist, in a multiple-dose up-titration study. International Journal of Clinical Pharmacology and Therapeutics. 53(9). 788–798. 16 indexed citations

12.

Baldoni, Daniela, Shirin Bruderer, Andreas Krause, et al.. (2014). A New Reversible and Potent P2Y12 Receptor Antagonist (ACT-246475): Tolerability, Pharmacokinetics, and Pharmacodynamics in a First-in-Man Trial. Clinical Drug Investigation. 34(11). 807–818. 34 indexed citations

13.

Baldoni, Daniela, Ulrika Furustrand Tafin, Alessandra Oliva, et al.. (2013). Activity of dalbavancin, alone and in combination with rifampicin, against meticillin-resistant Staphylococcus aureus in a foreign-body infection model. International Journal of Antimicrobial Agents. 42(3). 220–225. 51 indexed citations

14.

Baldoni, Daniela, Marcelo M. Gutierrez, Wolfgang Timmer, & Jasper Dingemanse. (2013). Cadazolid, a novel antibiotic with potent activity against Clostridium difficile: safety, tolerability and pharmacokinetics in healthy subjects following single and multiple oral doses. Journal of Antimicrobial Chemotherapy. 69(3). 706–714. 48 indexed citations

15.

Baldoni, Daniela, et al.. (2013). Setipiprant, a Selective Oral Antagonist of Human CRTH2: Relative Bioavailability of a Capsule and a Tablet Formulation in Healthy Female and Male Subjects. Clinical Therapeutics. 35(11). 1842–1848. 7 indexed citations

16.

Baldoni, Daniela, Andrea Steinhuber, Werner Zimmerli, & Andrej Trampuž. (2009). In Vitro Activity of Gallium Maltolate against Staphylococci in Logarithmic, Stationary, and Biofilm Growth Phases: Comparison of Conventional and Calorimetric Susceptibility Testing Methods. Antimicrobial Agents and Chemotherapy. 54(1). 157–163. 61 indexed citations

17.

Baldoni, Daniela, et al.. (2009). Performance of Microcalorimetry for Early Detection of Methicillin Resistance in Clinical Isolates ofStaphylococcus aureus. Journal of Clinical Microbiology. 47(3). 774–776. 69 indexed citations

18.

Baldoni, Daniela, Manuel Haschke, Katharina Rentsch, et al.. (2009). Efficacy of Daptomycin in Implant-Associated Infection Due to Methicillin-Resistant Staphylococcus aureus : Importance of Combination with Rifampin. Antimicrobial Agents and Chemotherapy. 53(7). 2719–2724. 146 indexed citations

19.

Baldoni, Daniela, Manuel Haschke, Z. Rajacic, Werner Zimmerli, & Andrej Trampuž. (2008). Linezolid Alone or Combined with Rifampin against Methicillin-Resistant Staphylococcus aureus in Experimental Foreign-Body Infection. Antimicrobial Agents and Chemotherapy. 53(3). 1142–1148. 85 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact